• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mayo Clin Proc Innov Qual Outcomes . Clinical Characteristics and Outcomes of Patients with SARS-CoV-2 Reinfection

tetano

Editor, Senior Moderator
Mayo Clin Proc Innov Qual Outcomes


. 2022 May 30.
doi: 10.1016/j.mayocpiqo.2022.05.004. Online ahead of print.
Clinical Characteristics and Outcomes of Patients with SARS-CoV-2 Reinfection


Isin Yagmur Comba[SUP] 1 [/SUP], Irene Riestra Guiance[SUP] 2 [/SUP], Cristina Corsini Campioli[SUP] 1 [/SUP], Douglas Challener[SUP] 1 [/SUP], Priya Sampathkumar[SUP] 1 [/SUP], Robert Orenstein[SUP] 3 [/SUP], Joel Gordon[SUP] 4 [/SUP], Wendelyn Bosch[SUP] 5 [/SUP], John C O'Horo[SUP] 1 2 [/SUP]



Affiliations

Abstract

Objective: To examine the clinical characteristics, risk of hospitalization and mortality of patients diagnosed with SARS-CoV-2 reinfection.
Patients and methods: We retrospectively reviewed all patients with SARS-CoV-2 reinfection all Mayo Clinic sites between May 23, 2020, and June 30, 2021 (the period before emergence of delta variant in United States). The reinfection was defined as positive SARS-CoV-2 test ≥ 90 days after initial infection or 45-89 days after with symptomatic second episode. Vaccination status was classified as fully vaccinated, first dose and unvaccinated. Comparative analysis of baseline characteristics and comorbidities was performed by hospitalization and vaccination status. The survival analysis of hospitalized patients was performed using cox-proportional hazard regression.
Results: Among 554 reinfected patients, 59 (10.6%) were pediatric, and 495 (89.4%) were adults. The median age was 13.9 years (interquartile range [IQR], 8.5-16.5) for pediatric and 50.2 years (IQR, 28.4-65.6) for adult population. Among adult patients, majority were unvaccinated (83.4%, n=413) and duration to reinfection from initial infection was longest in fully vaccinated group (p < .001). 42 (75%) out of 56 patients were seropositive within seven days of reinfection. In hospitalized adult patients, Charlson Comorbidity Index (CCI) was an independent risk factor for mortality (adjusted hazard ratio [aHR], 0.35; 95% CI, 0.19 to 0.51).
Conclusion: In this study, majority of adult patients with SARS-CoV-2 reinfection were unvaccinated. Furthermore, the duration to reinfection was longest in fully vaccinated individuals. Seropositivity was common among adult patients.

Keywords: BMI, body mass index; CCI, Charlson Comorbidity Index; CI, confidence interval.; COVID-19; COVID-19, coronavirus disease; HR, hazard ratio; IQR, interquartile range; RT-PCR, reverse transcriptase-polymerase chain reaction; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus; reinfection.
 
Back
Top Bottom